Patents Assigned to Santaris Pharma A/S
-
Patent number: 8163708Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.Type: GrantFiled: March 30, 2007Date of Patent: April 24, 2012Assignee: Santaris Pharma A/SInventors: Joacim Elmén, Phil Kearney, Sakari Kauppinen
-
Publication number: 20120088907Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: July 14, 2011Publication date: April 12, 2012Applicants: Santaris Pharma A/S, Enzon PharmaceuticalsInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20120083596Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.Type: ApplicationFiled: January 13, 2011Publication date: April 5, 2012Applicant: Santaris Pharma A/SInventors: Joacim Elmén, Phil Kearney, Sakari Kauppinen
-
Publication number: 20120004288Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.Type: ApplicationFiled: September 14, 2011Publication date: January 5, 2012Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.Inventor: Jesper WORM
-
Publication number: 20110319471Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.Type: ApplicationFiled: May 31, 2011Publication date: December 29, 2011Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.Inventor: Jesper WORM
-
Patent number: 8084458Abstract: Methods are described for the synthesis of Locked Nucleic Acid (LNA) derivatives using certain nitrogen-containing nucleophiles.Type: GrantFiled: August 3, 2009Date of Patent: December 27, 2011Assignee: Santaris Pharma A/SInventors: Mads Detlef Sørensen, Jesper Wengel, Troels Koch, Signe M. Christensen, Christoph Rosenbohm, Daniel Sejer Pedersen
-
Patent number: 8039446Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.Type: GrantFiled: September 2, 2010Date of Patent: October 18, 2011Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventor: Jesper Worm
-
Patent number: 8026355Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: April 22, 2010Date of Patent: September 27, 2011Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.Inventors: Jens Bo Rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20110224285Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 27, 2010Publication date: September 15, 2011Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Høg, Paul E.G. Kristjansen
-
Patent number: 7989429Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.Type: GrantFiled: March 18, 2010Date of Patent: August 2, 2011Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventor: Jesper Worm
-
Publication number: 20110183931Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.Type: ApplicationFiled: April 4, 2011Publication date: July 28, 2011Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Majken Westergaard, Charlotte A. Thrue, Frank W. Rasmussen, Henrik F. Hansen
-
Publication number: 20110144185Abstract: The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer.Type: ApplicationFiled: July 1, 2009Publication date: June 16, 2011Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/SInventor: Jesper Worm
-
Publication number: 20110124709Abstract: The present invention relates to oligomer compounds (oligomers), which target GLI2 mRNA in a cell, leading to reduced expression of GLI2. Reduction of GLI2 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.Type: ApplicationFiled: July 15, 2009Publication date: May 26, 2011Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/SInventor: Maj Hedtjarn
-
Patent number: 7939507Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.Type: GrantFiled: June 3, 2009Date of Patent: May 10, 2011Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Majken Westergaard, Charlotte Albaek Thrue, Frank Winther Rasmussen, Henrik Frydenlund Hansen
-
Publication number: 20110086902Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.Type: ApplicationFiled: September 2, 2010Publication date: April 14, 2011Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.Inventor: Jesper WORM
-
Publication number: 20110077288Abstract: The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.Type: ApplicationFiled: March 9, 2009Publication date: March 31, 2011Applicant: Santaris Pharma A/SInventors: Sakari Kauppinen, Niels Abrahamsen, Elisabeth Hildebrandt-Eriksen, Martin Munk
-
Publication number: 20110077285Abstract: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using the oligomers, including methods of treatment.Type: ApplicationFiled: November 17, 2010Publication date: March 31, 2011Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/SInventor: Maj Hedtjarn
-
Patent number: 7915401Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.Type: GrantFiled: January 21, 2009Date of Patent: March 29, 2011Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventor: Jesper Worm
-
Patent number: 7863437Abstract: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.Type: GrantFiled: November 26, 2008Date of Patent: January 4, 2011Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventor: Maj Hedtjarn
-
Publication number: 20100323967Abstract: Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1 are provided. Examples of such diseases include cancer and systemic mastocytosis.Type: ApplicationFiled: December 5, 2008Publication date: December 23, 2010Applicant: Santaris Pharma A/SInventors: Jens Bo Rode Hansen, Anja Mølhart Høg